DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B



Summary

The DisTinGuish trial Part B investigated the combination of DKN-01, a DKK1 inhibitor, and tislelizumab, an anti-PD-1 antibody, as a second-line treatment for patients with advanced gastroesophageal adenocarcinoma characterized by high DKK1 expression. Preliminary findings suggest that this combination showed encouraging clinical activity in this patient population. The trial explored safety and efficacy, providing insights into the potential of targeting the DKK1 pathway in combination with immunotherapy to improve outcomes for patients with DKK1-high gastroesophageal adenocarcinoma who have progressed on prior therapy. Further data and analysis are needed to confirm these initial observations.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!